 |
|
|
|
|
Product Details:
Payment & Shipping Terms:
|
| Name: | Mycophenolate Mofetil | Cas: | 115007-34-6 |
|---|---|---|---|
| Mf: | C23H31NO7 | Purity: | 99% |
| Appearance: | White Powder | Package: | 1kg/bag Or 25kgs/drum |
| High Light: | Mycophenolate Mofetil Powder,115007-34-6 Raw Materials,Mycophenolate Chemical Product |
||
CAS 115007-34-6 Mycophenolate Mofetil Raw Materials with 99% Purity Mycophenolate Mofetil Original Powder
Product Name:Mycophenolate mofetil
Molecular Formula: C23H31NO7
Molecular Weight: 433.49
CAS: 115007-34-6
Appearance: White or almost-white crystalline powder
Basic Information
| Product name | Mycophenolate mofetil |
| CAS | 115007-34-6 |
| Appearance | white powder |
| Assay | 99% |
| Storage | Cool and Protect from light |
Description
Mycophenolate mofetil (MMF), whose trade name is "Cellcept", was developed by the American Syntex Company. It is the semisynthetic derivative of mycophenocli acid (MPA) which is separated out from the glycolysis product of mold Penicillin glaucum. Mycophenolate mofetil is reusable cytostatics who have a history of clinical application being more than 10 years. It is mainly used for the treatment of psoriasis. At late 1980s, animal experiments have confirmed that it can significantly prolong the survival time of the allogeneic transplanted organs such as kidney, heart and islet of rodents. Sollinger et al has successfully applied MMF to the treatment of anti-rejection reaction upon kidney transplant for the first time with a remarkable effect. FDA has approved officially for its registration in 1995 under the trade name "Cellcept", making clinical applications been added into a new and effective immunosuppressant for prevention and treatment of rejection reaction.Chemical PropertiesWhite or almost white, crystalline powder.
| Adenosine | AR | 58-61-7 | ≥99% |
| Uridine | UR | 58-96-8 | ≥99% |
| Cytidine | CR | 65-46-3 | ≥99% |
| Xanthosine 5-monophosphate disodium salt | XMP- Na2 | 25899-70-1 | ≥98% |
| Inosine-5'-monophosphate disodium salt octahydrate | IMP- Na2 | 20813-76-7 | ≥98% |
| Adenosine 5′-monophosphate disodium salt | AMP- Na2 | 4578-31-8 | ≥98% |
| Adenosine 5'-Monophosphatesodiumsalt | AMP- Na | .13474-03-8 | ≥98% |
| 5-Adenylic acid | AMP | 61-19-8 | ≥98% |
| Adenosine 3',5'-cyclic monophosphate | Cyclic AMP,CAMP | 60-92-4 | ≥97% |
| Uridine 5-monophosphate, disodium salt | UMP- Na2 | 3387-36-8 | ≥98% |
| Uridine 5'-monophosphate | UMP | 58-97-9 | ≥98% |
| Cytidine 5''-monophosphate disodium salt | CMP- Na2 | .6757-06-8 | ≥98% |
| Cytidine 5′-monophosphate | CMP | 63-37-6 | ≥98% |
| Citicoline sodium | CDPC-Na | 33818-15-4 | ≥98% |
| uridine 5'-diphosphate disodium salt | UDP-Na2 | 27821-45-0 | ≥95% |
| IDP-K2 | ≥90% | ||
| Inosine-5'-diphosphoric acid disodium salt | IDP-Na2 | 54735-61-4 | ≥90% |
| Cytidine 5'-Diphosphate Trisodium Salt Hydrate | CDP-Na3 | 34393-59-4 | ≥90% |
| Cytidine-5'-diphosphate disodium salt | CDP-Na2 | 54394-90-0 | ≥90% |
| Adenosine 5'-diphosphate dipotassiuM salt | ADP-K2 | 114702-55-5 | ≥95% |
| Adenosine-5'-diphosphate, MonopotassiuM salt | ADP-K | 72696-48-1 | ≥95% |
| Adenosine-5-diphosphate disodium salt | ADP-Na2 | 16178-48-6 | ≥95% |
| Adenosine 5''-diphosphate sodium salt | ADP-Na | 20398-34-9 | ≥95% |
| Adenosine 5''-diphosphate | ADP | 58-64-0 | ≥95% |
| Uridine 5'-triphosphate disodium salt | UTP-Na3 | 19817-92-6 | ≥90% |
| Uridine-5'-triphosphoric acid trisodium salt | UTP-Na2 | 285978-18-9 | ≥90% |
| CTP-Na3 | ≥95% | ||
| Cytidine 5′-triphosphate disodium salt | CTP-Na2 | 36051-68-0 | ≥95% |
| Adenosine 5'-triphosphate disodium salt | ATP-Na2 | 987-65-5 | ≥95% |
| Adenosin-5'-triphosphat | ATP | 56-65-5 |
Contact Person: July
Tel: 25838890
